Overview

REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men

Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
Phase:
N/A
Details
Lead Sponsor:
Boston Scientific Corporation
Treatments:
5-alpha Reductase Inhibitors
Adrenergic alpha-Antagonists